Alterity Therapeutics Presents Positive Phase 2 Data for ATH434 in MSA at AAN Meeting

summarizeSummary

Alterity Therapeutics announced new analysis from its ATH434 Phase 2 trial, demonstrating clinical efficacy in Multiple System Atrophy patients and reinforcing its profile for Phase 3.

check_boxKey Events

• Positive Phase 2 Data Presented

  Alterity Therapeutics presented new analysis from its ATH434 Phase 2 trial at the American Academy of Neurology Annual Meeting, demonstrating clinical efficacy in Multiple System Atrophy (MSA) patients.

• Functional Decline Reduced

  The analysis showed ATH434 reduced functional decline versus placebo at Week 52 on the newly described MuSyCA composite scale, which is designed to improve detection of disease progression.

• Efficacy Reinforced for Phase 3

  The observed effects on daily function and neurological examination are consistent with previously reported activity, reinforcing ATH434's clinical profile ahead of Phase 3 engagement with regulators.

auto_awesomeAnalysis

This filing provides the detailed positive clinical data from the previously announced late-breaker presentation at the American Academy of Neurology Annual Meeting. The new analysis using the MuSyCA composite scale showed ATH434 reduced functional decline in MSA patients, consistent with prior findings. This reinforces the drug's efficacy and strengthens the company's position as it prepares for Phase 3 regulatory engagement, which is critical for a development-stage biotech.